Advanced Melanoma: Enfortumab Vedotin with Pembrolizumab

We are studying a combination of two treatments for patients with advanced melanoma who have been previously treated. The goal is to see if this combination is effective and safe for improving patient outcomes.

≤5 visitsEfficacy phase (II)No PlaceboStandard MedicinesInjectionOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Keytruda
Keytruda is a cancer medicine that helps the immune system find and fight tumor cells.
Padcev
Padcev is a cancer medicine used to treat advanced or metastatic bladder cancer in adults.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Enfortumab Vedotin
Enfortumab vedotin is a targeted cancer substance used to treat advanced or metastatic urothelial (bladder) cancer after prior therapies.
Pembrolizumab
Pembrolizumab is a substance that helps the immune system recognize and attack certain cancers by blocking a protein called PD-1.

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Complexo Hospitalario Universitario A Coruna
Medical Oncology
A Coruña, Spain
Hospital Universitari Dexeus Grupo Quironsalud
Medical Oncology
Amorebieta, Spain
Institut Catala D'oncologia
Medical Oncology
Badalona, Spain
Sponsor: Grupo Espanol Multidisciplinar De Melanoma
Last updated: Nov 27, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.